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Abstract 
 
Objective: Symptoms of chronic fatigue syndrome (CFS) can be perpetuated by cognitive 
and behavioural responses to the illness. We aimed to determine the factor structure, 
reliability and validity of the 40-item Cognitive Behavioural Responses Questionnaire 
(CBRQ) using data gathered from CFS patients.  We also propose a short version CBRQ 
for greater clinical utility. 
Methods: The psychometric analysis was performed on datasets drawn from two 
sources: a clinical service for CFS patients (N=576) and the PACE randomised controlled 
trial (RCT) of CFS treatments (N=640). An exploratory factor analysis (EFA) was 
conducted on the clinical dataset and a confirmatory factor analysis (CFA) was performed 
on the RCT dataset. Using these results, a short version of the CBRQ was proposed. 
Reliability, metric invariance across age and sex, and construct validity were assessed. 
Results: The EFA (relative Chi-square 2.52; RMSEA 0.051; CFI 0.964; TLI 0.942) and 
CFA (relative Chi-square 4.029; RMSEA 0.069; CFI 0.901; TLI 0.892) revealed that eight 
factor models fitted the data well. Satisfactory Cronbach’s alpha values were obtained for 
the final subscales (≥0.76). The shortened CBRQ was obtained by removing items that 
cross-loaded onto other factors and/or were the lowest loading items in each factor. The 
shortened CBRQ contained 18 items which had high factor loadings, good face-validity 
and reliability (Cronbach’s alpha 0.67-0.88).  
Conclusions: The CBRQ, long and short versions, are reliable and valid scales for 
measuring cognitive and behavioural responses of patients with CFS. Further research is 
needed to examine the utility of the CBRQ in other long-term conditions. 
 
Keywords: Psychometrics, Reliability, Validity, chronic fatigue syndrome, CBRQ, 
Instrument development 
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Acronyms 
AIC = Akaike information criterion  
BIC = Bayesian information criterion  
CBRQ = Cognitive and Behavioural Response Questionnaire 
CBT = Cognitive behavioural therapy 
CFA = Confirmatory factor analysis  
CFI = Comparative fit index  
CFQ = Chalder fatigue scale 
CFS = Chronic fatigue syndrome   
EFA = Exploratory factor analysis  
HADS = Hospital Anxiety and Depression Scale  
ME = Myalgic encephalomyelitis  
MIMIC = Multiple indicator multiple cause  
ML = Maximum likelihood  
PACE = Pacing, graded activity, and cognitive behaviour therapy: a randomised 
evaluation  
RMSEA = Root mean square error of approximation 
RCT = Randomised controlled trial  
SF36 = Medical Outcomes Study Short Form Health Survey  
TLI = Taylor–Lewis Index  
WLSMV = Weighted least squares means and variance adjusted estimator  
WSAS = Work and social adjustment scale 
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1. Introduction 
 
Chronic fatigue syndrome (CFS), or myalgic encephalomyelitis (ME), is a disorder that is 
characterised by severe and debilitating fatigue that is not alleviated by rest, persists for 
more than six months and has no identified medical cause (1). CFS patients often have 
difficulty working and recovery without treatment is uncommon (2, 3).  
 
Most studies have found that CFS patients do not have significant differences in 
physiological test results compared to controls (e.g., 4, 5). Shortly after its recognition as 
an illness (6, 7), clinical researchers postulated a cognitive behavioural model of CFS that 
hypothesised that CFS symptoms are perpetuated by the patients’ cognitive and 
behavioural responses to the illness (8, 9). Some of the unhelpful cognitive responses in 
patients with CFS include excessive focusing on fatigue symptoms (10), and catastrophic 
interpretations of symptoms which involves worrying about worst-case potential 
consequences (11). These cognitive responses are also associated with behavioural 
responses in CFS patients, which include reducing or avoiding activities to alleviate 
fatigue (12, 13), or alternating between high levels of activity when feeling well and resting 
excessively in response to symptoms. Activity avoidance in some CFS patients can be 
associated with the belief that activity can exacerbate their symptoms or it may also result 
from the embarrassment that they feel when experiencing fatigue symptoms in a social 
context.   
 
The therapies that have been shown to be effective in CFS, such as cognitive behavioural 
therapy (CBT) (14) are based on identifying and targeting unhelpful cognitive and 
behavioural patterns in CFS patients (9). It follows that accurate measurement of these 
factors is critical to the assessment of whether treatments are working as expected and to 
the refinement of treatments, so that they have the maximum possible effect on changing 
beliefs and behaviours that perpetuate CFS symptoms. 
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The Cognitive and Behavioural Response Questionnaire (CBRQ) is a 40-item self-rated 
questionnaire that was designed to measure these cognitive and behavioural responses 
to patients’ illness symptoms. In the development phase the scale was found to have five 
cognitive subscales and two behavioural subscales (15).  It was subsequently used to 
assess symptom beliefs in patients with CFS (16, 17, 18). The cognitive subscales 
include fear avoidance, catastrophising, damaging beliefs, embarrassment avoidance, 
and symptom focusing. Four subscales assess the interpretation of symptoms, whilst 
symptom focusing assesses the attentional focus towards symptoms. The behavioural 
subscales consist of all-or-nothing behaviour and avoidance/resting behaviour. Table S1 
in Supplemental Digital Content 1 describes the CBRQ items that make up the subscales. 
These subscales were based on a previously completed preliminary analysis, which was 
reported in conference proceedings (15). The aims of this paper were to see if the seven 
factor subscale structure (15) would be confirmed using new data sources, or whether a 
different subscale structure would be more appropriate, and to formally assess the validity 
of the CBRQ items. No formal psychometric analysis of the CBRQ has been published as 
yet. We also propose a shorter version of the CBRQ, based on the psychometric analysis 
results of the full questionnaire that retains cognitive and behavioural items and test the 
reliability and validity of this short version. Through the development and implementation 
of this short version of the CBRQ, we hope to reduce participant burden, reduce the risk 
of having random responses, and also obtain a questionnaire with as strong indicators as 
possible (by removing problematic items). 
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2.0 Methods 
2.1 Participants 
CBRQ data were drawn from two sources: a routine clinical service and the pacing, 
graded activity, and cognitive behaviour therapy: a randomised evaluation (PACE) trial 
((14); ISRCTN54285094). The CBRQ is a self-report questionnaire that the participants 
filled out on paper. Other measurements, such as the 36-item Medical Outcomes Study 
Short Form Health Survey (SF36) (19), Work and Social Adjustment Scale (WSAS) (20), 
Chalder Fatigue Scale (CFQ) (21), and anxiety and depression measured using the 
Hospital Anxiety and Depression Scale (HADS) (22) were also collected. For both 
datasets, only baseline measures were used in these analyses to avoid treatment effects. 
 
2.1.1 Clinical dataset 
Routine de-identified screening data were collected on 728 adult patients (≥18 years) that 
were assessed at the Chronic Fatigue Research and Treatment Unit in London, UK, 
between November 2007 and January 2014. These patients were selected in accordance 
with the Oxford criteria for diagnosing chronic fatigue syndrome (7).  All participants were 
medically assessed by the specialist clinic doctors to exclude alternative diagnoses (23).  
 
Patients were excluded from analysis if they: did not have CBRQ data (n=64); did not 
have a diagnosis of CFS (n=70); had bipolar (affective) disorder (n=4), an eating disorder 
(n=1), seizures (n=2), or cancer/were receiving chemotherapy (n=5) (1). Six entries were 
removed as they were duplicates of patients (original entries used). After 
inclusion/exclusion criteria were imposed, the sample was reduced to 576 patients.   
 
This data was collected as part of a clinical audit of routinely collected outcomes; an Audit 
and Service Evaluation Project Proposal Form was submitted and approved by South 
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London and Maudsley’s Psychological Medicine Clinical Academic Group Audit 
Committee and the clinical governance department, part of King’s Health Partners. 
 
 
2.1.2 RCT/PACE dataset 
Data were collected on 641 patients that were recruited into the PACE study (14) between 
March 18, 2005, and November 28, 2008. These patients were aged 18 years or older 
and were recruited from consecutive new outpatients attending six specialist CFS clinics 
in the UK National Health Service. The patients fulfilled the Oxford criteria for CFS, and 
specialist clinic doctors assessed the participants to exclude alternative diagnoses. The 
PACE study was approved by the West Midlands Multicentre Research Ethics Committee 
(MREC 02/7/89) and was the largest UK trial to date of CFS treatments. PACE included 
three therapies and one medical treatment for CFS. The main results of the trial have 
been reported elsewhere (14). One of the PACE participants withdrew consent for use of 
their data, so the final dataset was n = 640.  
 
2.2 Measures 
The CBRQ was used to assess the patients’ cognitive and behavioural responses to their 
symptoms. The development of the questionnaire is discussed elsewhere (Moss-Morris & 
Chalder, in preparation).   
 
Each CBRQ item is measured on a five-point Likert scale, scored from 0 (strongly 
disagree) to 4 (strongly agree), where a higher subscale score indicates more unhelpful 
cognitions and behaviours. Two of the items, FA2 and FA9, are reverse-scored. To 
calculate the totals, items FA2 and FA9 must first be reverse-coded, and the items in 
each of the subscales (Table S1 Supplemental Digital Content 1) are added together to 
create the subscale scores.  
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The SF36 (19), WSAS (20), CFQ (21) and HADS (22) were also used in the analysis to 
determine construct validity for the CBRQ. The SF36 health survey is a 36-item self-report 
survey of patient health, where a low score indicates greater impairment. The WSAS is a 
five-item self-report scale that measures impairment in work, home management, social 
activities, private leisure activities and relationships due to an identified problem. The 
CFQ is an 11-item self-report scale that measures symptoms of physical and mental 
fatigue. From this scale, a total score or a bimodal score can be obtained. The HADS is a 
14-item self-report instrument for detecting states of depression and anxiety in patients 
with medical illnesses. For the WSAS, CFQ and HADS high scores indicate greater 
impairment. These measures were collected in both datasets. 
 
2.3 Statistical Analyses 
2.3.1 Exploratory and Confirmatory Factor Analyses 
The factor structure of the CBRQ was assessed using factor analysis techniques for 
categorical data. Since no formal psychometric analysis of the CBRQ has been published, 
we began with an exploratory factor analysis (EFA) to determine possible factor 
structures. EFA was conducted with the clinical CFS dataset and confirmatory factor 
analysis (CFA) was performed with the RCT dataset. That is, the clinical dataset was 
used as a “learning” sample for EFA and the RCT dataset was used as the “testing” 
sample for CFA.  
 
When performing the EFA, 6-8 factor structures were initially examined as these 
produced fairly parsimonious models with good model fit and interpretability, and reflected 
previous results (15). Eigenvalues for the sample correlation matrix, scree plots and 
parallel analysis for categorical data (24) (using the package random.polychor.pa in R 
(25)) were also used to confirm this decision (results presented in Supplemental Digital 
Content 2, Figures S2.1 and S2.2). Initially all 40 items were included in the EFA. The 
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EFA was used to determine the factor structures, and reliability analyses were performed 
on these factor structures.  
 
Once the EFA was completed, CFA was performed with the RCT dataset to test these 
factor structures. A CFA using the 7-factor structure that was previously proposed (15); 
(Table S1, Supplemental Digital Content 1) was also performed.  The EFA and CFA were 
performed in Mplus (Version 7.4; (26)) to allow for handling of the categorical Likert-
scored data. For the EFA, GEOMIN rotation and the weighted least squares means and 
variance adjusted estimator (WLSMV) were used as recommended by (27). For the CFA, 
WLSMV was also used for estimation. We also employed the maximum likelihood (ML) 
estimator in CFA so that the Akaike information criterion (AIC) and Bayesian information 
criterion (BIC) values could be obtained in Mplus for fit comparison of non-nested models. 
 
2.3.2 Goodness-of-fit 
Model fit was assessed and compared using the relative Chi-square value (χ2/df, where 
values close to 2 indicate a good fit) (28), the root mean square error of approximation 
(RMSEA, where values less than 0.08 are required for an adequate fit) (29), the 
comparative fit index (CFI, values above 0.9 indicate a good fit) (30), the Taylor–Lewis 
Index (TLI, values above 0.9 indicate a good fit) (31), as well as the factor loadings and 
face-validity of the factors.  
 
2.3.3 Item Reduction 
To obtain the shortened version of the CBRQ, we removed items that had the lowest 
factor loadings (in each factor) and/or loaded saliently on more than one factor (cross-
loading) according to EFA results. EFA was used to determine the factor structure of the 
shortened scale (again, using the clinical dataset) and CFA was used to confirm the 
proposed shortened scale (using the RCT dataset). The final shortened version of the 
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CBRQ was chosen based on the item loadings, goodness-of-fit statistics, reliability 
indices, and the face-validity of the items in the factors (according to CFS experts).  
 
2.3.4 Reliability and Validity 
Reliability analyses, based on Cronbach’s alpha if item deleted and item-total correlation 
(within each factor), were conducted in SPSS (Version 22; SPSS, Inc, Chicago, IL, USA). 
Metric invariance across age (continuous) and sex, as well as dataset source (clinical or 
RCT dataset) was assessed using the multiple indicator multiple cause (MIMIC) structural 
equation model (32) in Mplus (Version 7.4). Construct validity was assessed by examining 
the correlations between the CBRQ total score and the SF36 total score, WSAS, CFQ, 
HAD total, HAD anxiety, and the HAD depression score. The results of the MIMIC 
analyses and construct validity are only presented for the shortened scale; the results for 
the full scale are available upon request. 
 
To check for the consistency in the factor structure between the two datasets, we pooled 
the RCT and clinical CFS datasets into one dataset and randomly split them into two 
datasets, and performed EFA on one sample and CFA on the other.   
 
All data available were used in these complete case analyses – no imputation of missing 
data was performed. In the clinical dataset, 0.7-1.7% of the values were missing in the 
CBRQ items. In the PACE dataset, 0.2-0.6% of the values were missing in the CBRQ 
items. 
 
3.0 Results 
3.1 Summary of datasets  
[Table 1 here] 
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The demographics of the RCT and clinical CFS datasets were quite similar in terms of the 
patients’ age, sex, and marital status (Table 1). There were some differences between the 
patients in terms of work status (P < 0.001) – more patients were temporarily unable to 
work in the RCT dataset compared to the clinical dataset (14.4% vs 23%), whereas the 
clinical dataset had more patients that were permanently unable to work due to illness 
(16% vs 3%). There were also more unemployed individuals in the RCT dataset (8.7% vs 
23.6%). There were also significant differences in ethnicity and highest educational 
qualifications between the two datasets. The duration of illness was generally longer in 
the clinical dataset compared to the RCT dataset (median 48 vs 31.5 months; P < 0.001). 
An inclusion criteria for the PACE study was that patients had a CFQ score ≥ 6; 473/576 
(82.1%) patients in the clinical dataset met this criteria. The mean CFQ score (bimodal) 
was 9.3 (SD=2.8) in the clinical dataset, and the mean in the RCT dataset was 10.3 
(SD=1.2) and a significant difference was found between these means (P < 0.001). PACE 
patients were also required to have an SF36 score ≤60, which was later increased to ≤65; 
348/576 (60.4%) patients had SF36 ≤60 in the clinical dataset and 377/576 (65.5%) 
patients had SF36 ≤65. The mean SF36 value in the clinical dataset was 46.9 (SD=26.4); 
the mean SF36 in the RCT dataset was 38 (SD=15.7) (P < 0.001). Due to trial entry 
criteria, the RCT patients had worse fatigue and disability than the clinical CFS patients. 
 
Regarding distribution of scores on the CBRQ subscales (scored using the original factor 
structure), the scores for the damage and embarrassment avoidance subscales were 
similar between the two datasets (Table 2); the fear avoidance, catastrophising, symptom 
focusing, all-or-nothing and avoidance/resting subscales had significant differences 
between the two datasets in terms of their distribution. In particular, the median scores for 
the all-or-nothing and avoidance/resting subscales were higher in the RCT dataset (Table 
2). Boxplots for the subscales for each dataset are displayed in Figure S1 in 
Supplemental Digital Content 1. 
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[Table 2 here] 
3.2 EFA and CFA results 
The eigenvalues for the full sample correlation matrix indicated that up to eight factors 
would be sufficient (see Figure S2.1, Supplemental Digital Content 2). Parallel analysis 
also indicated that up to eight factors should be considered (see Figure S2.2, 
Supplemental Digital Content 2 – this is the point immediately before where the plots of 
the observed (Polychoric correlation Empirical FA line) and simulated eigenvalues cross 
one another  (34)).  
 
EFAs using routine clinical data revealed that the best fitting model that included all items 
was the eight factor model (relative Chi-square 2.52; RMSEA 0.051 (90% CI: 0.048, 
0.055); CFI 0.964; TLI 0.942). The seven factor model also produced a good model fit 
(relative Chi-square 3.10; RMSEA 0.060 (90% CI: 0.057, 0.064); CFI 0.946; TLI 
0.920).The factor loadings and reliability for the eight factor model can be found in Table 
3. The factor loadings for the seven factor model may be found in Supplemental Digital 
Content 2 (Table S2.1). Since the fit indices are similar between the seven and eight 
factor models, one could choose the seven factor model on the grounds of parsimony. 
However, we argue that the eight factor model better explained the different subscales of 
the CBRQ since it separated the avoidance and the resting items into two factors and was 
more interpretable. Each factor in the eight factor model had satisfactory reliability 
(Cronbach’s alpha >0.7; (35)) and the item-total correlations (within each factor) were 
between 0.44 and 0.78 (data not shown). Summary statistics for the eight subscales 
obtained from the EFA and CFA and the total CBRQ score are given in Supplemental 
Digital Content 3 
 
Apart from the factor on which the items had their largest loading, the items L3, L4 and 
L11 loaded also on the fear avoidance subscale; the items EA3 and EA4 loaded on both 
12 
 
the embarrassment avoidance subscale and the avoidance subscale; items SF1, SF3 and 
L10 loaded also on the catastrophising subscale; items C1 and C2 loaded also on the 
damage subscale; items C4 and C6 loaded also on the symptom focusing subscale. 
 
[Table 3 here] 
 
CFA using the RCT dataset demonstrated that the seven factor model (using the original 
subscale structure) produced the best model fit (relative Chi-square 3.867; RMSEA 0.067 
(90% CI: 0.064, 0.070); CFI 0.905; TLI 0.897; AIC 60282.085; BIC 61258.805). The eight 
factor structure found during the EFA also produced a good model fit (relative Chi-square 
4.029; RMSEA 0.069 (90% CI: 0.066, 0.071); CFI 0.901; TLI 0.892; AIC 60408.311; BIC 
61416.250). 
Similar results were obtained when the two datasets were pooled and randomly split into 
two datasets with one dataset used for the EFA and the other used for CFA (results 
available upon request). 
 
 
4. Shortened version of CBRQ 
We chose to focus on the factor loadings in the eight factor model as it had a more 
distinct factor structure. Based on the results of the EFA and CFA, we have proposed a 
shortened version of the CBRQ. We wanted to develop a shorter version of the CBRQ so 
that it would take a shorter amount of time for the patients to fill out, provided that the 
psychometric properties of the CBRQ would be improved by removing some items.  
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4.1 Model fit 
 
Initially we removed all items with the lowest loadings within each factor and/or had cross-
loading in the eight factor model loadings (Table 3), and performed an EFA. We were 
interested in having a questionnaire with as strong indicators as possible, and so we then 
omitted the (remaining) weakest items in each factor so that we had at least three items in 
each factor, whilst ensuring minimal impact on reliability. The items removed were not 
considered essential according to TC, in terms of content validity. The factor structure for 
the final version of the shortened CBRQ is presented in Table 4, along with the 
Cronbach’s alpha value of each subscale. Summary statistics for each subscale and the 
total score for the shortened CBRQ are presented in Supplementary Digital Content 4. 
 
[Table 4 here] 
 
The EFA showed that a six factor model fit the data well: relative Chi-square 1.10; 
RMSEA 0.013 (90%: 0.00, 0.029); CFI 0.999; TLI 0.999. The CFA also confirmed that this 
six factor model provided a good fit: relative Chi-square 2.60; RMSEA 0.050 (90% CI: 
0.043, 0.057); CFI 0.983; TLI 0.978. There were no cross-loadings in the shortened 
questionnaire. The Cronbach’s alpha values for the factors within the shortened 
questionnaire indicated that the factors were reliable as the majority of the values were 
above 0.7. Comparing Tables 3 and 4, it can be seen that the reliability is almost 
unchanged in the shortened version of the CBRQ, even though there was a reduction in 
the number of items. It is not surprising that the Cronbach’s alpha values have slightly 
decreased since it is a function of the number of items. The shortened version of the 
CBRQ was thought to have good face-validity by CFS clinicians. The six factor model 
(with 18 items) explained 67% of variance in the data, whereas the eight factor model 
(with 40 items) explained 60% of the variance in the data. The short version CBRQ is 
presented in Supplementary Digital Content 5. 
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4.2 Metric invariance (MIMIC models) 
We ran the MIMIC models using the shortened questionnaire structure presented in Table 
4. Initially, we ran a MIMIC model to see if there was metric invariance in the items for the 
dataset source (RCT or clinical dataset). That is, we used MIMIC models to look at 
whether the loadings of the items to their corresponding factors differed according to the 
dataset source for people with the same underlying trait score.  We then ran MIMIC 
models within each dataset to see if the items’ factor loadings differed for the individuals’ 
age (continuous) or sex (for the same underlying trait score). The items that had metric 
non-invariance for dataset source are summarised in Table S6.1, and the items that had 
metric non-invariance for age and/or sex are summarised in Table S6.2 in Supplementary 
Digital Content 6.  
 
[ 
 
Based on the MIMIC analyses, there were a number of items in the dataset that appeared 
to have significantly different loadings across dataset source).  The effect size from the 
MIMIC models were large for the AL3 and L7 items; moderate for the EA2, L2 items; and 
small for SF5 and AL1 (37, 38). Some items had significant metric non-invariance for sex 
or age (EA1 and L2 for sex in RCT dataset; FA10 and L7 for age in clinical dataset; L2 for 
age in RCT dataset). However in most cases (for instance, FA10) the effect size was 
small (37, 38). Future research is required to test the replicability of these effects.  
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4.3 Construct validity 
Construct validity can be assessed by comparing the measure of interest to a similar (or 
different) measure. There are currently no other scales which specifically measure CFS 
patients’ views/beliefs about their symptoms. Instead, we assessed evidence towards 
construct validity by examining the correlations between the shortened CBRQ total score 
and other measures of impairment: the SF36 total score, WSAS, CFQ, HAD total score, 
HAD anxiety score, and the HAD depression score (Table 5). The shortened version of 
the CBRQ had significant correlation with these impairment measures which were low to 
moderate in size. 
[Table 5 here] 
5.0 Discussion 
5.1 Summary of main findings 
In this paper we investigated the subscale structure of the CBRQ to determine whether 
the scale originally developed by Moss-Morris and Chalder (in preparation) and used by 
(16, 17, 18) in CFS populations, was reliable and valid, or whether a different subscale 
structure was more appropriate. We also proposed a short version of the CBRQ which 
consisted of 18 items and was derived using the results from the EFA and CFA, as well 
as the expertise of CFS clinicians. 
EFA was carried out on data from routine clinical practice (n=576) and then CFA was 
conducted using data collected as part of a large RCT (14) (n=640). Similar results were 
obtained from both the EFA and CFA where seven and eight factor models produced the 
best fits. The original subscale/factor structure proposed by Moss-Morris and Chalder (in 
preparation) fit the data well. However, it appeared that the avoidance and resting items 
should be split into two factors since the resting items had high cross-loading in a seven 
factor model. This makes sense since at face value, these items appear to measure 
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different constructs. Large Cronbach’s alphas (34) were obtained for all the final 
subscales.  
 Although the catastrophising items have been used in previous papers (16, 17) and 
catastrophising was found to be one of the mediators of the effects of CBT and GET for 
CFS, we found these items to be problematic, with low factor loadings and evidence that 
they cross-loaded on to other factors. It may be that the items were not specific enough 
and/or overlapped with other constructs. In the proposed short version of the 
questionnaire we have removed these items since we wanted to obtain a questionnaire 
with as strong indicators as possible. The six factor model (with 18 items) explained 67% 
of variance in the data, whereas the eight factor model (with 40 items) explained 60% of 
the variance in the data. By removing problematic items, the latent structure became 
clearer. 
We also removed the avoidance items from the short version of the questionnaire as they 
cross-loaded on the fear avoidance factor or the catastrophising factor. It is likely that 
these items are not required in the presence of the fear avoidance items. The 
subscales/factors in the short version had good reliability and the items had large factor 
loadings and no cross-loading.  
MIMIC models indicated that there may be metric non-invariance in certain items in the 
short version, i.e., that the loadings of the items on their corresponding factors may differ 
according to age, sex, or dataset source for people with the same underlying latent trait 
score. The magnitude of the estimates can inform us as to the degree of metric non-
invariance present. The effect size estimates for metric non-invariance for dataset source 
were quite large for some of the items (AL3 and L7), which means that the relationship 
between these items and the trait differs according to the dataset.  This could be 
explained by the fact that PACE patients had to meet certain criteria to be included in the 
clinical trial and these patients had more self-reported disability (Section 3.1).  
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It is important to note that the effect size estimates for the items that had significant metric 
non-invariance across age and/or sex (Table S6.2, Supplemental Digital Content 6) are 
small (37), the largest odds ratio being 1.56.  One could use the methods proposed by 
(38) to convert the log odds ratios to a Cohen’s d value, and come to the same 
conclusion. This suggests that age and sex differences in the loadings might not be 
reproduced in smaller samples and should be explored in future research. It may be the 
case that females respond differently to men in their thinking and coping styles, and older 
patients may respond differently to younger patients due to experience. Future analyses 
could adjust for the items that had metric non-invariance for sex and/or age. 
 
We used only baseline data in this study to focus on measurement avoiding the effects of 
treatment. Although we did not examine the post treatment measures of the CBRQ in this 
study, future studies will use longitudinal data analyses of the routine clinic dataset to 
investigate whether the item responses change over time (test-retest reliability). This has 
been investigated to some extent where mediation analyses were performed using the 
different subscales of the CBRQ as mediators on the primary outcome (measured by the 
CFQ and the physical function subscale of the SF36) using the RCT dataset (17) and a 
clinical CFS dataset (16). 
 
5.2 Validity 
When assessing construct validity, correlations with theoretically similar measures, should 
be high, whilst correlations with theoretically dissimilar measures should be low. The short 
version CBRQ total score had significant and moderate, positive correlations with the 
WSAS, as well as the HAD total, HAD anxiety and HAD depression scores, which makes 
sense as increases in these measures correspond to more disability. The short version 
CBRQ had a small and positive correlation with the CFQ, which is not unexpected since 
CFQ measures fatigue, rather than patient beliefs. The short version CBRQ total score 
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had a small, negative correlation with the SF36 total score, which makes sense since a 
lower SF36 score corresponds to more disability. The SF36 measures physical function, 
rather than beliefs about symptoms, and so it is not unexpected that the SF36 and (short 
version) CBRQ have small correlations. 
The CBRQ scale has good face-validity and it also has good predictive validity since it 
changes over time with CBT (16).  The scale items were based on a model of 
understanding symptom perception in which cognitive and behavioural responses are all 
important in determining outcomes in terms of symptom severity and disability (9). Two 
recent studies which examined the role of cognitive behavioural responses as mediators 
during the process of CBT support the use of this measure as a predictive tool (16, 17).    
The clinic attenders and those who agreed to take part in the RCT may not be 
representative of the wider population of people with CFS. Those who agreed to take part 
in the RCT differed to those recruited in the clinic in that the routine clinic attenders had 
been ill for longer and were more ethnically diverse. Ingman et al. (18) found that black 
and minority ethnic individuals had more extreme baseline cognitive behavioural 
responses, but that these differences did not affect treatment outcome.  
This paper was not designed to assess aetiology of CFS; its main aim is to assess the 
reliability and validity of the CBRQ in people with CFS. The CBRQ is designed to assess 
cognitive behavioural responses in relation to symptoms and one cannot make 
assumptions about causality. As fatigue is ubiquitous these responses could be important 
in the context of other diseases.  
 
The short version of the CBRQ was developed using psychometric analyses performed 
on two datasets. This short version has not yet been piloted on patients, and so future 
analyses should re-validate this proposed short version of the CBRQ with an independent 
sample of patients that represent the same target population.  
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In summary, the long and short versions of the CBRQ, are reliable and valid scales for 
measuring cognitive and behavioural responses of patients with CFS. Further research 
examining the utility of the CBRQ in other conditions would be welcome. 
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Table 1. Demographics of patients in clinical and RCT datasets 
Variable Clinical dataset (n=576) RCT dataset (n=640) Comparison 
Sex Male:  148 (25.7%) 
Female:  428 (74.3%) 
Male: 145 (22.7%) 
Female: 495 (77.3%) 
P = 0.23 
Age 39 (18-80) 
 
38 (18-77) P = 0.40 
Time with CFS 
(months) 
48 (2.3-492) 31.5 (5-382)  P < 0.001 
Ethnicity White:  420 (72.9%) 
Other: 81 (14%) 
None given: 23 (4%) 
Missing: 52 (9%) 
White: 595 (93%) 
Other: 40 (6.2%) 
None given: 5 (0.8%) 
P < 0.001 
Marital status Single: 251 (43.6%) 
Married/living together: 261 
(45.3%) 
Separated/divorced/widowed: 55 
(9.5%) 
Missing: 9 (1.6%) 
Single: 249 (38.9%) 
Married/living together: 332 
(51.9%) 
Separated/divorced/widowed: 
59 (9.2%) 
  
P = 0.12 
Highest educational 
qualifications 
None: 16 (2.8%) 
Secondary school: 130 (22.6%) 
University: 290 (50.3%) 
Other: 129 (22.3%) 
Missing: 11 (1.9%) 
None: 24 (3.8%) 
Secondary school: 237 (37%) 
University: 312 (48.8%) 
Other: 67 (10.5%) 
P < 0.001 
Work status Working (fulltime, part time, 
casual): 243 (42.2%) 
Student: 33 (5.7%) 
Unable to work/study 
temporarily due to illness: 83 
(14.4%) 
Unable to work permanently due 
Working (fulltime, part time, 
casual): 240 (37.5%) 
Student: 20 (3.1%) 
Unable to work/study 
temporarily due to illness: 147 
(23%) 
Unable to work permanently 
P < 0.001 
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to illness: 92 (16%) 
Unemployed: 50 (8.7%) 
Retired (due to age): 19 (3.3%) 
Looking after the home: 29 (5%) 
Missing: 27 (4.7%) 
due to illness: 19 (3%) 
Unemployed: 151 (23.6%) 
Retired (due to age): 3 (0.5%) 
Look after the home: 20 (3.1%) 
Other: 40 (6.3%) 
Data are presented as numbers (%) or medians (range).  
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Table 2. Medians and ranges of clinical measures in clinical dataset and RCT 
dataset 
Subscale Potential 
range 
Clinical dataset 
(n=576) 
RCT dataset 
(n=640) 
Comparison 
Mann-Whitney U-
test p-value 
Fear avoidance  
 
0-24 14 (1-24) 15 (2-24) 
 
P < 0.001 
Catastrophising  
 
0-16 8 (0-16) 8 (0-16) 
 
P = 0.015 
Damage  
 
0-20 11 (0-20) 11 (0-20) P = 0.42 
Embarrassment 
avoidance  
 
0-24 12 (0-24) 12 (0-24) P = 0.44 
Symptom 
focusing  
 
0-24 14 (0-24) 13 (0-24) P = 0.011 
All-or-nothing  
 
0-20 9 (0-20) 14 (4-20) P < 0.001 
Avoidance/resting  
 
0-32 13 (1-31) 19 (5-31) P < 0.001 
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Table 3. Factor loadings (in descending order for each factor) for eight-factor model 
obtained from EFA (GEOMIN Rotation) performed on the clinical dataset, n=576  
  
Factor 
 1 2 3 4 5 6 7 8 
FA1 0.723 0.001 0.086 -0.001 0.07 -0.002 0.03 -0.066 
FA12 0.697 -0.054 -0.046 0.082 0.01 0.089 -0.036 0.057 
FA2 0.571 0.010 -0.01 0.049 -0.018 -0.114 -0.125 0.030 
FA17 0.564 0.150 -0.028 0.044 0.113 0.051 0.029 0.019 
FA3 0.547 0.121 -0.046 0.088 0.036 -0.023 0.235 -0.027 
FA14 0.432 0.068 0.085 -0.029 -0.114 0.095 0.003 -0.020 
         
FA10 0.016 0.818 0.055 -0.002 -0.040 0.062 -0.064 0.021 
FA4 0.052 0.808 0.047 -0.019 -0.050 -0.046 -0.045 0.008 
FA9 -0.192 0.709 -0.005 0.091 0.033 -0.023 0.011 0.097 
FA15 0.161 0.615 -0.116 -0.024 0.168 0.038 0.038 -0.001 
FA16 0.159 0.412 0.079 -0.002 0.123 0.030 0.135 -0.089 
         
SF5 -0.009 0.035 0.858 -0.021 -0.004 0.029 0.113 -0.022 
SF12 -0.048 0.056 0.842 -0.027 -0.004 -0.040 0.131 -0.063 
SF1 0.087 -0.095 0.763 0.306 0.028 -0.023 -0.076 0.058 
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SF3 0.078 -0.036 0.662 0.346 -0.042 0.028 -0.007 0.011 
SF9 -0.016 0.076 0.660 0.008 0.012 0.055 0.094 -0.012 
SF2 -0.067 0.170 0.573 0.179 0.092 0.003 -0.030 0.018 
         
C2 -0.030 0.354 0.054 0.731 -0.005 -0.013 -0.009 -0.033 
C1 0.068 0.296 0.022 0.657 -0.065 -0.007 0.055 0.049 
C6 -0.019 0.003 0.253 0.431 0.047 -0.029 -0.021 0.018 
C4 0.041 0.132 0.260 0.350 0.097 0.069 0.098 0.058 
         
EA1 0.033 -0.057 0.067 -0.027 0.909 -0.024 -0.058 0.039 
EA2 0.021 -0.017 0.076 -0.052 0.872 0.068 -0.037 -0.001 
EA5 -0.004 0.011 -0.030 0.035 0.855 -0.007 0.027 0.031 
EA6 -0.06 0.083 0.016 0.034 0.653 -0.053 0.146 -0.020 
EA3 0.010 0.065 -0.020 0.216 0.513 0.031 0.316 0.001 
         
AL3 0.006 -0.022 0.048 -0.047 -0.033 0.885 -0.040 0.054 
AL2 0.008 0.041 -0.055 0.179 0.015 0.822 -0.018 -0.028 
AL1 0.113 0.010 -0.004 0.073 0.021 0.786 -0.011 -0.054 
AL4 -0.020 -0.042 0.011 -0.047 -0.013 0.742 0.076 0.183 
AL5 -0.053 0.084 0.034 0.015 0.103 0.511 0.170 0.050 
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L11 0.343 -0.018 0.038 -0.054 -0.025 -0.065 0.658 0.101 
L10 -0.037 -0.081 -0.003 0.286 0.065 0.067 0.653 0.033 
EA4 0.003 -0.014 -0.009 0.304 0.281 0.058 0.593 -0.141 
L4 0.348 0.044 0.016 -0.045 -0.042 -0.048 0.570 0.151 
L13 0.063 0.016 0.087 0.066 -0.019 -0.009 0.556 0.035 
         
L9 0.001 -0.005 0.003 0.079 0.044 0.030 0.009 0.853 
L7 -0.001 -0.001 -0.028 0.103 0.007 0.039 -0.037 0.750 
L2 0.000 0.118 -0.012 0.004 0.047 -0.027 0.077 0.628 
L3 0.270 0.015 0.064 -0.114 -0.04 0.033 0.214 0.496 
         
Cronbach’s 
alpha*: 0.76 0.80 0.89 0.77 0.88 0.87 0.80 0.80 
The questions for each of the item abbreviations are written out in full in Supplemental Digital Content 1. The 
highest factor loading for each item is boldfaced. Items that have cross-loading (35, 36) on a factor are both 
boldfaced and italicised in their loading value. *The Cronbach’s alpha values were obtained using the 
(boldfaced) items that make up each subscale. 
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Table 4. Factor loadings for proposed shortened version of the CBRQ obtained 
from EFA (GEOMIN Rotation) performed on the clinical dataset, n=576  
Factor 
 1 2 3 4 5 6 
FA1 0.720       -0.005          0.182        0.039          0.000 -0.036 
FA2 0.574    0.057         -0.021         -0.047         -0.110 0.022 
FA12 0.710             -0.003    -0.020          0.007          0.095 0.087 
FA4 0.064      0.849        -0.008         -0.012         -0.037 -0.039 
FA9 -0.128       0.639         0.042          0.054         -0.002 0.107 
FA10 0.016          0.839         0.004         -0.023          0.074 -0.003 
SF5 0.007         -0.006          0.929        -0.014          0.017 0.023 
SF9 0.022          0.055          0.712         0.025          0.063 0.014 
SF12 -0.019         -0.001          0.912         0.001         -0.059 -0.012 
EA1 0.005                 -0.009        -0.001          0.914 -0.029 0.001 
EA2 -0.011         -0.001          0.033          0.869         0.056 -0.013 
EA5 0.017          0.015         -0.020 0.849         0.000 0.046 
AL1 0.077       -0.007       0.037          0.022          0.824 -0.045 
AL2 0.014                  0.041         -0.033 0.027          0.891 0.021 
AL3 -0.027                     -0.016     0.007 -0.033          0.819 0.040 
L2 -0.023          0.115        -0.004          0.040         -0.014 0.624 
L7 0.016         -0.027          0.007         -0.043          0.054 0.762 
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L9 0.026         -0.005          0.012          0.014         -0.014 0.920 
Cronbach’s 
alpha*: 
0.67 0.79 0.85 0.88 0.86 0.79 
The questions for each of the item abbreviations are written out in full in Supplemental Digital Content 1. The 
highest factor loading for each item is boldfaced. *The Cronbach’s alpha values were obtained using the three 
items that make up each subscale. 
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Table 5. Correlation (P-value) between total score from proposed shortened version 
of CBRQ and selected measures  
Variable Correlation (P) 
in clinical 
dataset (n=576) 
SF36 total score -0.25 (<0.001) 
WSAS 0.35 (<0.001) 
CFQ 0.20 (<0.001) 
HAD anxiety 0.46 (<0.001) 
HAD depression 0.45 (<0.001) 
HAD total score 0.52 (<0.001) 
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Supplemental Digital Content 
Supplemental Digital Content 1 – Original CBRQ Subscales 
 
Table S1. Original 7 factors/subscale model for the CBRQ 
  
F1. Fear avoidance I am afraid that I will make my symptoms worse if I 
exercise (FA1) 
My symptoms would be relieved if I were to exercise 
(FA2) 
Avoiding unnecessary activities is the safest thing I can do 
to prevent my symptoms from worsening (FA3) 
Physical activity makes my symptoms worse (FA12) 
Doing less helps symptoms (FA14) 
I should avoid exercise when I have symptoms (FA17) 
 
F2. Catastrophizing  I worry that I may become permanently bedridden because 
of my symptoms (C1) 
I think that if my symptoms get too severe they may never 
decrease (C2)  
My illness is awful and I feel that it overwhelms me (C4) 
I will never feel right again(C6) 
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F3. Damage The severity of my symptoms must mean there is 
something serious going on in my body (FA4) 
Even though I experience symptoms, I don’t think they are 
actually harming me (FA9) 
When I experience symptoms, my body is telling me that 
there is something seriously wrong. (FA10) 
Symptoms are a signal that I am damaging myself (FA15) 
I am afraid I will have more symptoms if I am not careful 
(FA16) 
 
F4. Embarrassment 
avoidance 
I am embarrassed about my symptoms (EA1) 
I worry that people will think badly of me because of my 
symptoms (EA2) 
The embarrassing nature of my symptoms prevents me 
from doing things (EA3) 
I avoid social situations because I am scared my symptoms 
will get out of control (EA4) 
I am ashamed of my symptoms (EA5) 
My symptoms have the potential to make me look foolish in 
front of other people (EA6) 
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F5. Symptom focusing When I experience symptoms, I think about them 
constantly (SF1) 
I worry when I am experiencing symptoms (SF2) 
When I am experiencing symptoms it is difficult for me to 
think of anything else (SF3) 
I think a great deal about my symptoms (SF5) 
My symptoms are always at the back of my mind (SF9) 
I spend a lot of time thinking about my illness (SF12) 
 
F6. All-or-nothing behaviour I tend to overdo things when I feel energetic (AL1) 
I find myself rushing to get things done before I crash (AL2) 
I tend to overdo things and then rest up for a while (AL3) 
I tend to do a lot on a good day and rest on a bad day 
(AL4) 
I'm a bit all or nothing when it comes to doing things (AL5) 
 
F7. Avoidance/resting 
behaviour 
I stay in bed to control my symptoms (L2) 
When I experience symptoms, I rest (L3) 
I tend to avoid activities that make my symptoms worse 
(L4) 
I tend to nap during the day to control my symptoms (L7) 
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I sleep when I'm tired in order to control my symptoms (L9) 
I avoid making social arrangements in case I'm not up to it 
(L10) 
I avoid exerting myself in order to control my symptoms 
(L11) 
I avoid stressful situations (L13) 
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Figure S1. Boxplots for the original subscale structures in each data set 
 
38 
 
 
 
  
39 
 
Supplemental Digital Content 2 – EFA performed on Clinical CFS 
data 
 
Figure S2.1. Scree plot for the EFA performed on the clinical CFS data 
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Figure S2.2 Parallel analysis scree plot for the EFA performed on the clinical CFS 
data 
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Table S2.1 Factor loadings for seven-factor model obtained from EFA (GEOMIN 
Rotation) performed on the clinical dataset, n=576  
 1 2 3 4 5 6 7 
FA1 0.718 0.008 0.077 -0.026 -0.045 0.043 -0.008 
FA2 0.537 0.01 0.008 -0.126 -0.072 -0.07 0.132 
FA3 0.599 0.129 -0.009 0.04 0.133 -0.011 0.03 
FA12 0.685 -0.054 -0.018 -0.073 0.01 0.132 0.158 
FA14 0.424 0.072 0.068 -0.184 -0.009 0.117 -0.02 
FA17 0.563 0.16 -0.019 0.035 0.025 0.089 0.083 
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FA4 0.04 0.834 0.031 -0.158 -0.021 -0.027 -0.023 
FA9 -0.182 0.719 0.034 0.004 0.084 -0.023 0.088 
FA10 -0.001 0.843 0.046 -0.146 -0.021 0.082 -0.009 
FA15 0.166 0.643 -0.141 0.095 0.022 0.059 0.009 
FA16 0.185 0.428 0.073 0.098 0.015 0.037 -0.096 
        
C1 0.124 0.254 0.358 0.066 0.024 -0.038 0.458 
C2 0.026 0.302 0.42 0.131 -0.082 -0.044 0.456 
C4 0.074 0.11 0.426 0.163 0.091 0.065 0.168 
C6 -0.005 -0.03 0.464 0.123 -0.035 -0.035 0.229 
SF1 0.051 -0.131 0.914 0.015 -0.03 0.003 0.054 
SF2 -0.089 0.152 0.662 0.073 -0.022 0.018 -0.022 
SF3 0.074 -0.075 0.835 -0.017 -0.019 0.038 0.063 
SF5 -0.027 0.022 0.864 -0.042 0.064 0.04 -0.272 
SF9 -0.024 0.065 0.671 -0.011 0.056 0.063 -0.194 
SF12 -0.056 0.044 0.847 -0.032 0.039 -0.034 -0.299 
        
EA1 -0.019 -0.031 0.007 0.887 -0.064 0.031 0.027 
EA2 -0.024 0.008 0.008 0.854 -0.075 0.113 -0.02 
EA3 0.086 0.069 0.069 0.62 0.201 0.025 0.061 
EA4 0.163 -0.019 0.132 0.508 0.295 0.007 -0.042 
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EA5 -0.024 0.033 -0.052 0.865 -0.001 0.031 0.06 
EA6 -0.044 0.103 0.008 0.686 0.057 -0.037 -0.02 
        
L2 -0.02 0.115 -0.033 -0.004 0.6 -0.009 0.385 
L3 0.273 0.024 -0.008 -0.099 0.585 0.051 0.202 
L7 -0.053 -0.019 0.001 -0.052 0.635 0.059 0.559 
L9 -0.047 -0.014 0.014 -0.025 0.741 0.059 0.585 
L4 0.466 0.057 -0.014 0.045 0.532 -0.067 -0.073 
L10 0.151 -0.088 0.127 0.335 0.458 0.01 -0.014 
L11 0.483 -0.004 0.004 0.096 0.553 -0.092 -0.141 
L13 0.198 0.015 0.117 0.142 0.416 -0.049 -0.118 
        
AL1 0.116 0.011 0.018 0.044 -0.052 0.792 -0.01 
AL2 0.022 0.035 0.02 0.074 -0.04 0.817 0.07 
AL3 -0.012 -0.017 0.008 -0.038 0.037 0.888 -0.035 
AL4 -0.016 -0.037 -0.029 0.006 0.225 0.741 0.027 
AL5 -0.017 0.092 0.027 0.157 0.164 0.503 -0.041 
The questions for each of the item abbreviations are written out in full in Supplemental Digital Content 1. The 
highest factor loading for each item is boldfaced. Items that have cross-loading on a factor are both boldfaced 
and italicised in their loading value. 
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Supplemental Digital Content 3 – Summary statistics for the eight 
subscales obtained from EFA/CFA performed on full (40-item) 
CBRQ  
 
Table S3.1 Medians (IQR) and ranges of each of the eight subscales (obtained from 
EFA/CFA) in clinical dataset and RCT dataset 
Subscale Potential range Clinical dataset 
(n=576) 
RCT dataset 
(n=640) 
Comparison 
Mann-Whitney U-
test p-value 
Fear avoidance  
(FA1, FA2, FA3, 
FA12, FA14, FA17) 
 
0-24 14 (11-17) 
Min: 1; Max: 24 
15  (12-18) 
Min: 2; Max: 24 
 
P < 0.001 
Catastrophising  
(C1, C2, C4, C6) 
 
0-16 8 (6-11) 
Min: 0; Max: 16 
8 (5-10) 
Min: 0; Max: 16 
 
P = 0.015 
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Damage  
(FA4, FA9, FA10, 
FA15, FA16) 
 
0-20 11 (8-13) 
Min: 0; Max: 20 
11 (9-13) 
Min: 0; Max: 20 
P = 0.42 
Embarrassment 
avoidance  
(EA1, EA2, EA3, 
EA5, EA6) 
 
0-20 11 (7-14) 
Min: 0; Max: 20 
11 (7-14) 
Min: 0; Max: 20 
P=0.57 
Symptom focusing  
(SF1, SF2, SF3, 
SF5, SF9, SF12) 
 
0-24 14 (10-17) 
Min: 0; Max: 24 
13 (10-16) 
Min: 0; Max:24 
P = 0.011 
All-or-nothing 
(AL1, AL2, AL3, 
AL4, AL5)  
 
0-20 9 (6-14) 
Min: 0; Max: 20 
14 (11-16) 
Min: 4; Max: 20 
P < 0.001 
Avoidance  
(EA4, L4, L10, L11, 
L13) 
 
0-20 9 (6-13) 
Min: 0; Max: 20 
12 (9-14) 
Min: 1; Max: 20 
P < 0.001 
Resting 
(L2, L3, L7, L9) 
0-16 6 (4-8) 
Min: 0; Max: 16 
9 (7-11) 
Min:1; Max: 16 
P < 0.001 
Total CBRQ 0-160 82 (68-97) 
Min: 14; Max: 145 
91 (78-105) 
Min:29; Max: 152 
P < 0.001 
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Cronbach’s alpha 
for all items: 0.928 
Cronbach’s alpha 
for all items:0.914 
The questions for each of the item abbreviations are written out in full in Supplemental Digital Content 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.1 Boxplots for the Embarrassment avoidance, Avoidance, and Resting subscale 
scores for each dataset. (These are the only subscales to have changed from the original 
subscale structure) 
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Supplemental Digital Content 4 – Summary statistics for the six 
subscales obtained from EFA/CFA performed on reduced (18-
item) CBRQ  
 
Table S4.1 Medians (IQR) and ranges of each of the six subscales in the reduced 
CBRQ (obtained from EFA/CFA) in clinical dataset and RCT dataset 
Subscale Clinical dataset 
(n=576) 
RCT dataset 
(n=640) 
Comparison 
Mann-Whitney U-
test p-value 
Fear avoidance  
(FA1, FA2, FA12) 
 
7 (6-9) 
Min: 0; Max: 12 
8 (6-9) 
Min: 1; Max: 12 
P=0.016 
Damage  
(FA4, FA9, FA10) 
 
7 (5-9) 
Min: 0; Max: 12 
6 (5-8) 
Min: 0; Max: 12 
P=0.48 
Embarrassment 
avoidance  
(EA1, EA2, EA5) 
 
7 (4-9) 
Min: 0; Max: 12 
7 (4-9) 
Min: 0; Max: 12 
P=0.28 
Symptom focusing  
(SF5, SF9, SF12) 
 
7 (5-9) 
Min: 0; Max: 12 
7 (5-9) 
Min: 0; Max: 12 
P=0.001 
All-or-nothing 
(AL1, AL2, AL3)  
6 (3-9) 
Min: 0; Max: 12 
9 (7-10) 
Min: 1; Max: 12 
P < 0.001 
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Resting 
(L2, L7, L9) 
3 (2-6) 
Min: 0; Max: 12 
7 (4-8) 
Min: 0; Max: 12 
P < 0.001 
Total CBRQ 38 (31.5-44) 
Min: 8; Max: 65 
Cronbach’s alpha 
for all (18) items: 
0.824 
42 (36-48) 
Min:11; Max: 69 
Cronbach’s alpha 
for all (18) items: 
0.814 
P < 0.001 
The questions for each of the item abbreviations are written out in full in Supplemental Digital Content 1. The 
possible range of scores for each subscale is 0-12. 
 
Supplemental Digital Content 5 – Short version CBRQ 
 
Table S5.1 Short version of the CBRQ (18 items) 
 
  
F1. Fear avoidance I am afraid that I will make my symptoms worse if I 
exercise (FA1) 
My symptoms would be relieved if I were to exercise 
(FA2) 
Physical activity makes my symptoms worse (FA12) 
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F2. Damage The severity of my symptoms must mean there is 
something serious going on in my body (FA4) 
Even though I experience symptoms, I don’t think they are 
actually harming me (FA9) 
When I experience symptoms, my body is telling me that 
there is something seriously wrong. (FA10) 
 
F3. Embarrassment 
avoidance 
I am embarrassed about my symptoms (EA1) 
I worry that people will think badly of me because of my 
symptoms (EA2) 
I am ashamed of my symptoms (EA5) 
 
F4. Symptom focusing I think a great deal about my symptoms (SF5) 
My symptoms are always at the back of my mind (SF9) 
I spend a lot of time thinking about my illness (SF12) 
 
F5. All-or-nothing behaviour I tend to overdo things when I feel energetic (AL1) 
I find myself rushing to get things done before I crash (AL2) 
I tend to overdo things and then rest up for a while (AL3) 
 
F6. Resting behaviour I stay in bed to control my symptoms (L2) 
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I tend to nap during the day to control my symptoms (L7) 
I sleep when I'm tired in order to control my symptoms (L9) 
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Supplemental Digital Content 6 - Metric invariance (MIMIC 
models) 
 
Table S6.1. Items that did not have metric invariance across dataset source (clinical 
dataset or RCT dataset) based on CFA performed on proposed short version of 
CBRQ. 
Item Estimate (SE) P 
SF5 -0.446 (0.172) 0.009 
EA2 0.559 (0.154) <0.001 
AL1 -0.427 (0.172) 0.013 
AL3 0.935 (0.176) <0.001 
L2 
L7 
-0.764 (0.157) 
2.340 (0.171) 
<0.001 
<0.001 
Estimates were obtained using the ML estimator and are presented on the log-odds scale. 
 
 
 
 
Table S6.2. Items that did not have metric invariance for age and/or sex based on 
CFA performed on proposed short version of CBRQ.  
  Clinical dataset (n=576) RCT dataset (n=640) 
Variable Items  Estimate (SE) P Estimate (SE) P 
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Sex 
 
EA1 
L2 
- 
- 
- 
- 
0.364 (0.114) 
-0.198 (0.072) 
0.001 
0.006 
Age  FA10 
L2 
L7 
0.021 (0.009) 
- 
0.038 (0.010) 
0.020 
- 
<0.001 
- 
0.447 (0.187) 
- 
- 
0.017 
- 
Estimates were obtained using the ML estimator and are presented on the log-odds scale. Note that ‘-‘ 
indicates that the item did not have metric non-invariance in that dataset.  
 
 
